About Protara Therapeutics, Inc.
Protara is committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
March 8, 2023
March 1, 2023
February 2, 2023
January 30, 2023
March 14, 2023 at 1:20 PM EDT
March 8, 2023 at 9:50 AM EST
February 9, 2023 at 11:20 AM EST
September 12, 2022 at 7:00 AM EDT